$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.02% on an annualized basis producing an average annual return of 19.86%. Currently, Novo Nordisk has a market capitaliza

BenzingaJul 4 23:00

NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss

Yahoo FinanceJul 4 20:19

Novo Nordisk's Weight-Loss Drug Retains Safety Profile Despite Concerns -- Market Talk

1204 GMT - Novo Nordisk's semaglutide--the active ingredient in its blockbuster weight-loss and diabetes treatments--belongs to one of the most derisked therapeutic drug classes in history from a safe

WSJJul 4 20:04

A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.

A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.

Zhitong FinanceJul 4 14:42

Can it cause blindness? Research shows that the weight loss drug Ozempic is related to a rare blindness condition, and weight loss drug concept stocks have fallen.

Hidden risk of rare blindness.

Gelonghui FinanceJul 4 11:52

A Harvard study shows a link between weight loss drug Ozempic and rare vision loss, causing a nearly 5% drop in novo-nordisk a/s stocks.

Some doctors have pointed out that there is currently no evidence to prove a direct causal relationship between drug use and eye complications, as some cases only appear after several months of medication.

wallstreetcnJul 4 08:31